-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 4, Shenzhou Cell issued an announcement stating that its holding subsidiary, Shenzhou Cell Engineering, received the "Drug Clinical Trial Approval" approved and issued by the State Food and Drug Administration.
The approval document 2021L90025 is the single-drug clinical research plan of SCTA01C, and the approval document 2021L90026 and 2021L90027 are the clinical research plan of SCTA01C and SCTA01 combination drugs
SCTA01 is a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody independently developed by Shenzhou Cell Engineering.
SCTA01C is a new coronavirus monoclonal neutralizing antibody independently developed by Shenzhou Cell Engineering.
SCTA01C and SCTA01 bind to different epitopes of RBD respectively, and can bind to the same RBD together